How Will COVID-19 Change Pediatric Care?
A new paper highlights the means by which child healthcare, a “human science,” will rebound from the pandemic.
Related Articles
Long-term Risankizumab Treatment Outperforms Placebo in PsA
Treatment with risankizumab was shown to be an effective strategy among patients with PsA regardless of varying demographic and psoriatic disease characteristics through 1 year.
Thoracic Ultrasound Refines Detection of ILD in Rheumatoid Arthritis
Thoracic ultrasound examination may be applicable as a screening method for interstitial lung disease in patients with RA and respiratory symptoms.
Calliditas Announces Open Label Extension Results for Budesonide (Nefecon) in IgA Nephropathy
Positive topline results showed treatment response consistent with NefIgArd findings, regardless of whether participants had previously been treated with Nefecon or placebo.
Phase 3 Data on Brilaroxazine for Schizophrenia with Larry Ereshefsky, PharmD
In an interview with HCPLive, Larry Ereshefsky, PharmD, discussed the phase 3 RECOVER trial assessing brilaroxazine at 50 mg and 15 mg for acute schziophrenia.
Guselkumab, Risankizumab Boast Longest Drug Survival Among IL-17, IL-23 Inhibitors
A recent meta-analysis of more than 60 studies suggests guselkumab and risankizumab had the longest drug survival of IL-17 and IL-23 inhibitors for psoriasis.
ACP’s New Type 2 Diabetes Guidance Recommends SGLT2is, GLP-1 RAs as Second-Line to Metformin
The American College of Physicians released new recommendations for the management of type 2 diabetes with inadequate glycemic control using metformin or other first-line therapies.
2024 State of the Air: Record Highs in US Particle Pollution, with John Balmes, MD
Balmes discusses the latest annual State of the Air Report, which shows that 131 million Americans are living in areas with failing air quality grades.
Sharon K. Inouye, MD, MPH: Why is Delirium During Hospitalization Not Taken Seriously?
This ACP Conference interview featured a discussion with Inouye about gaps in knowledge regarding patients experiencing delirium during hospitalization.
Guselkumab, Risankizumab Boast Longest Drug Survival Among IL-17, IL-23 Inhibitors
A recent meta-analysis of more than 60 studies suggests guselkumab and risankizumab had the longest drug survival of IL-17 and IL-23 inhibitors for psoriasis.
Risankizumab Significantly Improves Skin, Joint Symptoms in PsA
Post-treatment with risankizumab, the cDAPSA score, PGA score, and PASI score substantially decreased among a cohort of patients with psoriatic arthritis.